Regencell Bioscience Holdings Limited (RGC)

33.00 -1.90 (-5.44%) At close: 04:00PM EST

Regencell Bioscience Holdings Limited

First Commercial Building
11th Floor 33-35 Leighton Road
Causeway Bay KY1-1107
Hong Kong
852 2155 0823
https://www.regencellbioscience.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 13

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Tien Hsiang Chau	Chief Financial Officer	123.61k	N/A	1970
Mr. Wai Hong Chung	COO & Chief Strategy Officer	245.64k	N/A	1977
Dr. Yi-Chung Chao Ph.D.	Chief Medical Officer & Director	249.74k	N/A	1964
Mr. Yat-Gai Au	Founder, Chairman & CEO	N/A	N/A	1973

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Corporate Governance

Regencell Bioscience Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.